New engine of multi land economic development with overall acceleration of biomedical industry

[China Pharmaceutical network industry trends] the pharmaceutical industry has become one of the strategic business cards for the rapid development of many regions in China In the pharmaceutical industry, biomedical industry is a priority area in many provinces and cities In order to achieve the effect of developing biomedicine, many provinces and cities have invested a lot of energy to build the development highland of biomedical industry, so as to form a complete industrial chain Ten key biomedical projects in Banan District of Chongqing were launched on August 3 The 2018 key projects of investment promotion were launched in Banan District of Chongqing In the main venue of Chongqing biomedical industrial park (Chongqing Maliu Riverside Development Zone), 10 key biomedical projects, such as Peking University Medical, Sichuan new green and Chuan'an pharmaceutical industrial base, were started in a centralized manner, setting a new record for the number of one-time start-up of Chongqing biomedical enterprises in recent years This also marks the overall acceleration of industrial transformation and upgrading in Banan, the increase of "accelerator" in the biomedical industry, the roar of engines, and the acceleration of entering the fast lane of development According to the relevant person in charge, these 10 projects cover biopharmaceutical, chemical APIs and preparations, modern Chinese medicine and medical devices, which will form a complete industrial chain, not only to achieve resource sharing, but also to form a virtuous cycle of supply, and finally achieve the effect of mutual benefit In order to better achieve this effect, Banan District has built Chongqing biomedical industrial park, which will further accelerate the pace of industrial development It is one of the three pillar industries in Yongfeng county to vigorously promote the development of biomedical industry In recent years, Yongfeng County, in accordance with the development idea of "being a large-scale productive enterprise, invigorating the medical trade market, and strengthening the pharmaceutical base", focuses on "supporting large projects, cultivating large enterprises, building large clusters, and building large brands", promotes the development of the biomedical industry from small to large, with a structure from single to multiple, forming the oral liquid, tablet, medical equipment, and health care products of Chinese patent medicine , pesticide and other biomedical industry clusters It is reported that from 2013 to 2017, the main business income and tax revenue of Yongfeng biomedical industry quadrupled in four years In the first half of this year, the main business income of the biomedical industry in Yongfeng county was 1.58 billion yuan, accounting for 19.7% of the scale industry, and the tax paid was 98.12 million yuan, accounting for 28.1% of the scale industry The development of Pudong biomedical industry continues to add new momentum It is reported that the joint development mode of Pudong biomedical enterprises fully docking with "international advantageous resources" is increasing day by day The cooperative R & D projects of many enterprises have been accepted by the State Drug Administration and approved for clinical research For example, vorolanib (CM082), a new drug of kananji, a wholly-owned subsidiary of Beida pharmaceutical, and rerepli (js001), a new biological drug of Shanghai Junshi, are proposed to be jointly used for the clinical trial application of drugs for the local progress or metastatic mucosal melanoma that have not been treated before, which has been accepted by CNDA In addition, the human animal chimeric anti-CD30 monoclonal antibody mcc-dm1 coupling agent jointly developed by Shanghai Pharmaceutical and Shanghai Fudan Zhangjiang biomedical Co., Ltd has also been approved by CNDA for drug clinical trials The application category of the drug is class 1 new drug application of biological products for treatment Lanzhou New Area, Gansu Province, has built a pillar for the development of biomedical industry Through strengthening scientific and technological innovation, improving the industrial chain and other measures, the strength of biomedical enterprises has been significantly enhanced, and the biomedical industry has further gathered At present, Lanzhou New Area has initially formed a group of biomedical pillar enterprises led by heshengtang, foci, etc., and the trend of biomedical industry agglomeration has initially appeared According to the introduction of relevant personnel, the biomedical industry in Lanzhou new area is gradually forming a complete industrial chain It adheres to the goal of chemical, large-scale and international development, will be guided by variety R & D innovation, supported by the construction of specialized industrial parks, and accelerate the cultivation and development of biotechnology drugs It is reported that in 2017, the output value of biomedical industry in Lanzhou New Area reached 520 million yuan, accounting for 1.76% of the total industrial output value; the added value reached 87 million yuan, accounting for 1.74% of the industrial added value In the future, the completion value of biomedical industry in Lanzhou New Area will also show a trend of multiple growth.